Replies to post #7926 on RespireRx Pharmaceuticals Inc (fka RSPI)

[tonyvanw]

Neuro said: < I have in the past argued for negotiating from strength, and I do know that licensees look for companies who are fiscally weak, and build that into their strategies >

This I am sure is correct. Keep in mind also that if two or more BPs are competing for CX717, it will be the science and the product potential that will drive the deal, not the current COR cash balance.

[iggs]

Neuro:

Understand the market is down...Understand the warrant impact, but these levels are shocking given where they are with cx717.

What is your opinion on an inlicensing? Do you think that there are potential candidates(products)that COR should be looking at? What is your take on deals in the marketplace? Will they require much in terms of upfront cash? As you know, Cor has mentioned that they were going to pursue this strategy. Do you think that they might raise money via a pipe for this? (ie: Does your experience tell you that they might be able to do something accretive?)

If you were to play devils advocate, if the Co did raise a pipe do you have any thought as to what ($) they would raise and what the impact might be on SP? Do you think we are back under $2.00?

Do you have a sense for what might be going on with cx701?

Iggs